302-33-0

Basic information

• Product Name: Proadifen
• Synonyms: Proadifenum;2,2-Diphenylvaleric acid 2-(diethylamino)ethyl;HL-8727;RP-5171;Acetate, diethylaminoethyldiphenylpropyl;Benzeneacetic acid, alpha-phenyl-alpha-propyl-, 2-(diethylamino)ethyl ester;D011335;Diethylaminoethyldiphenylpropyl acetate
• CAS NO: 302-33-0
• Molecular Formula: C₂₃H₃₁NO₂
• Molecular Weight: 353.503
• Mol File: 302-33-0.mol
• Article Data: 1

Chemical Properties

• Boiling Point: 486.9°C (rough estimate)
• Flash Point: 132.3°C
• Appearance: /
• Density: 1.0678 (rough estimate)
• Vapor Pressure: 1.13E-08mmHg at 25°C
• Refractive Index: 1.5614 (estimate)
• PKA: 9.20±0.25(Predicted)
• CAS DataBase Reference: Proadifen(CAS DataBase Reference)
• NIST Chemistry Reference: Proadifen(302-33-0)
• EPA Substance Registry System: Proadifen(302-33-0)

Safety Data

• Hazardous Substances Data: 302-33-0(Hazardous Substances Data)

Usage

Uses

Synergist (non-specific).

Enzyme inhibitor

This nonselective P450 inhibitor (FWfree-base = 353.50 g/mol; CAS 302-33-0; 62-68-0 for the HCl salt), also known as SKF-525A, b-diethylaminoethyl 2,2-diphenylpropylacetate, and N,N-diethylaminoethyl 2,2- diphenylvalerate, blocks glibenclamide-sensitive K+ channels, including ATP-sensitive inward rectifier potassium channel 8 (KIR6.1). As a nonselective inhibitor of cytochrome P450 systems, proadifen also inhibits drug metabolism, thereby potentiating the action of many pharmaceuticals. For example, proadifen inhibits the demethylation of 2-methoxyestrogens . Target (s) : aldehyde oxidase; alkanal monooxygenase, FMN- linked; aromatase, or CYP19; bacterial luciferase, or alkanal monooxygenase, FMN-linked; benzoate 4-monooxygenase; bromomethane monooxygenase7; calcium influx8; ent-copalyl-diphosphate synthase; CYPC211; cytochrome P450; diamine N- acetyltransferase; N,N-dimethylaniline demethylase; ecdysone 20- monooxygenase; ethoxyresorufin O-deethylase; flavin-containing monooxygenase, or dimethylaniline-N-oxide aldolase; glyceollin synthase; 2-hydroxyisoflavanone synthase; 25-hydroxyvitamin D3 24-monooxygenase; isopentenyl-diphosphate D-isomerase, or isopentenyl-pyrophosphate D-isomerase; ent-kaurene synthase; leukotriene B4 20-hydroxylase; (S) -limonene 3-monooxygenase; (S) -limonene 6-monooxygenase; (S) -limonene 7-monooxygenase; methane monooxygenase; monoamine oxidase; NADPH:cytochrome P450 reductase; nitric-oxide synthase, neuronal ; pentoxyresorufin O-depentylase; phenol O-methyltransferase ; progesterone 11a-monooxygenase; steroid 11b-monooxygenase ; steroid 21-monooxygenase, or CYP21A1, weakly inhibited; sterol 14-demethylase, or CYP51; styrene monooxygenase; thiol S-methyltransferase; thromboxane production; and trimethylamine-oxide aldolase.

InChI:InChI=1/C23H31NO2/c1-4-17-23(20-13-9-7-10-14-20,21-15-11-8-12-16-21)22(25)26-19-18-24(5-2)6-3/h7-16H,4-6,17-19H2,1-3H3

Upstream product

• 13080-07-4 2,2-diphenyl-valeryl chloride 
• 100-37-8 2-(Diethylamino)ethanol 
• 86-29-3 Diphenylacetonitrile 
• 29949-16-4 2,2’-diphenylpentanenitrile 
• 841-32-7 SKF 2314 
• 101594-41-6 2,2-diphenylpentanal 

Relevant articles and documents

Molecular Modification of Anticholinergics as Probes for Muscarinic Receptors. Amino Esters of α-Substituted Phenylacetic Acid and Related Analogues

Two series of compounds having the general structure of C6H5CRR'COOCH2CH2NEt2 were synthesized and examined for their antispasmodic activities.These compounds were selected as structural probes for exploring the nature of muscarinic cholinergic receptor binding sites that interact with atropine-like anticholinergics.These studies indicate a rather strict size limitation for the hydrophobic region of the receptor and suggest intramolecular hydrogen bonding as a possible means to explain the observed stereoselectivity.